当前位置: 首页 > 期刊 > 《中国医学创新》 > 2011年第22期
编号:13187702
第三代芳香化酶抑制剂在绝经后乳腺癌新辅助内分泌治疗中的应用(4)
http://www.100md.com 2011年8月5日 《中国医学创新》 2011年第22期
     [15] Harvell DM, Spoelstra NS, Singh M,et al.Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of esponse or intrinsic resistance. Breast Cancer Res Treat,2008,112(3):475-488.

    [16] Ellis MJ, Coop A, Singh B,et al. Letrozole inhibits tumor roliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res,2003,63(19):523-6531.

    [17] Dowsett M, Ebbs SR, Dixon JM,et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen,or the combination independence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists.J Clin Oncol,2005,23(11):2477-2492.

    [18] Ellis MJ, Coop A, Singh B,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/orErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase Ⅲ randomized trial.J Clin,Oncol,2001,19(18): 3808-3816.

    [19] Barnadas A, Gil M, Sánchez-Rovira P, et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anti -cancer,2008,19(4):339-347.

    (收稿日期:2011-04-13)

    (本文编辑:王春芸), 百拇医药(王万忠 种瑞峰 郑敏 齐恒)
上一页1 2 3 4